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Human liver carboxylesterase 1 (CES1) plays a critical role in the hydrolysis of various ester- and
amide-containing molecules, including active metabolites, drugs and prodrugs. However, it has been
problematic to express recombinant CES1 in bacterial expression systems due to low solubility, with
the CES1 protein being mainly expressed in inclusion bodies, accompanied by insufﬁcient purity issues.
In this study, we report an efﬁcient in vitromethod for refolding recombinant CES1 from inclusion bodies.
A one-step puriﬁcation with an immobilized-metal afﬁnity column was utilized to purify His-tagged
recombinant CES1. Conveniently, both denaturant and imidazole can be removed while the enzyme is
refolded via buffer exchange, a dilution method. We show that the refolding of recombinant CES1 was
successful in Tris–HCl at pH 7.5 containing a combination of 1% glycerol and 2 mM b-mercaptoethanol,
whereas a mixture of other additives (trehalose, sorbitol and sucrose) and b-mercaptoethanol failed to
recover a functional protein. His-tagged recombinant CES1 retains its biological activity after refolding
and can be used directly without removing the fusion tag. Altogether, our results provide an alternative
method for obtaining a substantial amount of functionally active protein, which is advantageous for
further investigations such as structural and functional studies.
 2014 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Human liver carboxylesterase (CES1, EC number: 3.1.1.1,
3.1.1.56), an enzyme responsible for the hydrolysis of ester- and
amide-containing molecules, is mainly expressed in the liver
where it is crucial for the processing of active metabolites (heroin
and cocaine) and is also involved in trans-esteriﬁcation reactions
[1–4]. In addition, CES1 is known to play an important role in thehydrolysis of several classes of drugs and the activation of
prodrugs, including angiotensin-converting enzyme (ACE)1 inhibi-
tors and the anti-inﬂuenza agent oseltamivir [5–10], also known as
Tamiﬂu, a recommended treatment by the World Health Organiza-
tion (WHO). Oseltamivir is a prodrug in the form of oseltamivir
phosphate, which requires conversion into its active carboxylate
form by CES1. Two known CES1 mutations, G143E and p.D260fs,
have been shown to impair the function of the enzyme with regard
to the activation of oseltamivir, indicating the signiﬁcant role of CES1
in oseltamivir metabolism [8,9].
Extensive studies have been carried out to investigate the role
of CES1 in oseltamivir metabolism in terms of pharmacokinetics,
structure and function. Accordingly, different expression systems,
puriﬁcation processes and enzymatic assays have been established,
with most previous works employing conventional cell-culture
techniques to produce a functional enzyme. Mammalian cell lines,
COS7 and Flp-In-293 with the pCDNA5/FRT/V5-His TOPOTA
expression system, have frequently been utilized for the produc-
tion of CES1. Wild-type (WT) as well as mutant proteins have been
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and activation of several compounds mediated by CES1, such as p-
nitrophenyl acetate (pNPA), oseltamivir, methylphenidate,
trandolapril and clopidogrel and its metabolite [6–10]. Insect cells,
Sf9 and Sf21, are also preferred for expressing CES1, which is
accomplished using a baculovirus expression system [2,3,11,12].
In addition to insect cell culture, there was a report in which
Trichoplusia ni whole-insect larvae were used as a production
source of CES1 recombinant protein [13]. Finally, yeast expression
systems involving Saccharomyces cerevisiae and Pichia pastoris are
also used for the expression of CES1 [14]. Although eukaryotic
expression systems are suitable for expressing eukaryotic proteins,
especially when post-translational modiﬁcations are needed, they
are relatively complex, expensive and require long time periods
to obtain the desired protein compared to bacterial expression sys-
tems. Furthermore, eukaryotic expression systems typically yield
only small to moderate amounts of protein.
As an alternative to expression in eukaryotic cells, bacteria are
among the most extensively hosts used for protein production
because expressing proteins in bacterial systems is inexpensive
and easy to handle and large amounts of protein are achievable
[15,16]. A previous attempt to express CES1 in bacteria failed to
produce the functional protein because CES1 was mainly expressed
in inclusion bodies [14]. Indeed, this is a major problem with
expressing human proteins in bacteria, as the proteins are mis-
folded and aggregate, preventing the production of a functional
eukaryotic protein [17–20]. As a result, various methods have been
established to overcome insolubility issues: fusion tags and growth
temperature, auto-induction and puriﬁcation conditions have all
been optimized to improve the solubility of proteins expressed in
Escherichia coli [21–23]. Moreover, various types of folding aids
are employed in bacterial systems. E. coli molecular chaperones,
e.g., GroES and GroEL, have shown to promote protein folding
when co-expressed with human aromatase and aldehyde dehydro-
genase enzymes [24,25]. Additionally, it has been proven that
including some chemical chaperones, e.g., polyols, amino acids
and polyethylene glycol, in the growth medium is beneﬁcial for
producing soluble and functional proteins [26–28]. However, when
the aforementioned methods are unsuccessful and the protein is
still mainly expressed as inclusion bodies, efﬁcient protocols for
refolding proteins is, therefore, necessary to produce biologically
active proteins, which will be advantageous for structural and
functional studies. Many effective protocols for refolding proteins
from inclusion bodies have been established and proven to suc-
cessfully produce active enzymes. The refolding of proteins can
mainly be achieved in two different ways: dialysis and dilution.
During the refolding process, chemical chaperons or additives are
usually added to assist in protein conformation, and additives such
as trehalose, glycerol, sorbitol, arginine and sucrose have been
reported to be advantageous for the refolding step [17–19,29–33].
In the present study, we report the heterologous expression of
CES1 in E. coli, in which it was mainly expressed in inclusion
bodies. Thereafter, different refolding conditions were applied to
retain the catalytically active enzyme. In addition to WT CES1,
three natural variants (S76N, D204E and A270S) were expressed,
puriﬁed, refolded and characterized.Materials and methods
Plasmid constructs and site-directed mutagenesis
In this study, we investigated the expression, puriﬁcation and
refolding of CES1 isoform a (NCBI Reference Sequence:
NP_001020366.1), which is one and two amino acids longer than
isoforms b and c, respectively. Therefore, the numbering of aminoacid residues is herein shifted by one residue compared to previous
reports. The CES1 gene was ampliﬁed from human liver cDNA (BD
Biosciences) using Platinum Taq DNA polymerase (Life Technolo-
gies) with a forward primer GGATCCGAATTCCATCCGTCCTCGC
and a reverse primer GGTGCTCGAGTCACAGCTCTATGTG. The
ampliﬁed region was designed to start at amino acid 20, omitting
the ﬁrst 19 amino acids of the signal peptide to prevent complica-
tions of post-translational modiﬁcation. Two restriction enzyme
sites were introduced, EcoRI and XhoI, in the forward and reverse
primers, respectively (underlined). PCR products were gel puriﬁed
and digested with EcoRI and XhoI (New England Biolabs). The
digested amplicon (encoding 20–568 residues) was cloned into
the pET28a expression vector with an N-terminal His-tagged and
transformed into the E. coli expression host BL21 (DE3). Three con-
structs of CES1 natural mutations, S76N, D204E and A270S, were
generated using a site-directed mutagenesis kit (Agilent Technolo-
gies) with speciﬁc primers. All constructs were veriﬁed by bidirec-
tional DNA sequencing and restriction digestion to conﬁrm that the
desired plasmids were obtained.
Expression of recombinant CES1
A single colony of BL21 (DE3) harboring the recombinant
plasmid was inoculated in 5 ml of LB medium containing 50 lg/
ml kanamycin and incubated at 37 C with 250 rpm shaking over-
night. The fresh overnight cultures were inoculated in LB medium
in the presence of 50 lg/ml kanamycin at a dilution of 1:100 and
grown at 25 C with 250 rpm shaking until the absorbance at
600 nm (OD600) reached 0.3. Then, the cultures were induced with
isopropyl-b-D-thiogalactopyranoside (IPTG, Merck) at a ﬁnal con-
centration of 0.5 mM and were further incubated at 25 C with
200 rpm shaking for 4 h before being harvested by centrifugation
at 1000g for 10 min.
Puriﬁcation of recombinant CES1
The CES1 protein was puriﬁed under denaturing condition due
to its main expression in the insoluble fraction. Cell pellets were
resuspended in lysis buffer (20 mM sodium phosphate, pH 7.4,
300 mM NaCl, 10 mM imidazole and 2 mM b-mercaptoethanol)
and disrupted by sonication. The cell lysate was centrifuged at
20,000g for 45 min at 4 C, and the supernatant was removed.
To reduce protein interference, the pellet was washed with 2 M
urea in lysis buffer by incubating on ice for 15 min and then
subjected to centrifugation at 20,000g for 45 min at 4 C. The
inclusion bodies were solubilized in buffer A (lysis buffer contain-
ing 8 M urea) by incubating the solution on ice for 1 h. The solubi-
lized solution was centrifuged for 1 h at 20,000g and 4 C. The
supernatant was collected and incubated with pre-equilibrated
TALON Metal Afﬁnity Resin (BD Biosciences) in buffer A at 4 C
for at least 1 h. The unbound proteins were removed with wash
buffer (20 mM sodium phosphate, pH 7.4, 300 mM NaCl, 8 M urea,
20 mM imidazole and 2 mM b-mercaptoethanol; 4 times, 6 ml
each). The elution of CES1 was accomplished with elute buffer
(20 mM sodium phosphate, pH 7.4, 300 mM NaCl, 8 M urea and
250 mM imidazole, 2 mM b-mercaptoethanol; for 5 times, 4 ml
each).
In vitro refolding of recombinant CES1 using the dilution method
In the refolding step, urea (protein denaturant) and imidazole
were gradually removed via dilution. This procedure was
performed while the protein was refolded by buffer exchange with
50 mM Tris–HCl, pH 7.5, containing different combinations of addi-
tives and reducing agents (Table 1) using Amicon Ultra centrifugal
ﬁlter devices (Millipore). The protein solution was mixed with
Table 1
Refolding conditions for recombinant WT CES1.
Additive Reducing agent Catalytically active CES1
0.2 M trehalose 2 mM b-mercaptoethanol No
0.2 M sucrose 2 mM b-mercaptoethanol No
0.2 M sorbitol 2 mM b-mercaptoethanol No
1% glycerol 2 mM b-mercaptoethanol Yes
1% glycerol 2 mM DTT No
Fig. 1. Amino acid sequence of CES1 isoform a. The ﬁrst 19-amino acids, highlighted
in gray, comprise the signal peptide sequence, which was omitted during cloning.
Amino acids known to be associated with the biological function are boxed. Natural
variants created in our experiment are underlined. The N-glycosylation site is
circled, and disulﬁde bonds are shown by linkage of two cysteine residues.
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bucket) and 4 C for 10–15 min. The ﬂow-through was discarded;
the refolding buffer was added again, and the sample was centri-
fuged. The step was repeated until the ﬁnal concentration of both
urea and imidazole was less than 0.01 mM. The purity of protein
was visualized by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis (SDS–PAGE), and the enzymatic activity was measured
as described below. The protein concentration was measured by
the Nanodrop method [34] using an extinction coefﬁcient at
280 nm of 86,860 M1 cm1 calculated, as with the Protparam ser-
ver [35].
Intrinsic ﬂuorescence analysis
Intrinsic ﬂuorescence emission spectra of the refolded proteins
(WT and mutants) were collected using a Synergy H1 hybrid reader
(Biotek) with a 96-well plate at 25 C. The excitation wavelength
was 280 nm, and the emission spectra were monitored in the range
of 300–450 nm. All the spectra were collected after refolding CES1
in 50 mM Tris–HCl, pH 7.5, containing 1% glycerol and 2 mM b-
mercaptoethanol.
Circular dichroism (CD) spectrum analysis
Far UV-CD spectra were recorded using a Jasco spectrometer,
model J-815, with a 1 mm pathlength. The measurements were
carried out at room temperature. The spectra were collected over
a wavelength range of 190–260 nm. CD spectra for WT and the
three mutants were collected after refolding in 50 mM Tris–HCl,
pH 7.5, containing 1% glycerol and 2 mM b-mercaptoethanol. Three
scans were averaged for each protein sample, and the buffer was
also subtracted.
Enzyme activity assay
CES1 activity was measured spectrophotometrically by follow-
ing the conversion of pNPA to p-nitrophenol (pNP) at 405 nm using
a UV-2700 UV–VIS spectrophotometer (Shimadzu). The substrate
was dissolved in acetonitrile. The enzyme activity assay was
performed in a cuvette with a ﬁnal volume of 1 ml. In brief, the
reaction mixture containing 930 ll of 50 mM Tris–HCl, pH 7.5,
40 ll absolute ethanol and 10 ll of various concentrations of pNPA
was incubated at 37 C for 5 min. After that, 20 ll of puriﬁed
enzyme was added, and the reaction was further incubated at
the same temperature for 10 min. The absorbance 405 nm was
monitored for 10 min. Each reaction was conducted in four repli-
cates, and the initial linear measurement was used for determining
the slope of the initial velocity. Data from the spectrophotometer
were exported to Excel to calculate the rate of product formation
and were expressed as micromole of pNP produced per minute
per milligram protein (lmol/min/mg) as calculated using the
extinction coefﬁcient for pNP at 405 nm (18,000 M1 cm1).
Steady-state kinetic parameters, KM, kcat and Vmax, were obtained
by ﬁtting the collected data to the Michaelis–Menten equation
using GraphPad Prism software (GraphPad Software).Western blot analysis
A Western blot analysis was performed to conﬁrm the expres-
sion of recombinant CES1. Puriﬁed proteins were loaded onto a
12% SDS-PAGE, separated by electrophoresis and transferred onto
a polyvinylidene diﬂuoride (PVDF) membrane. The membrane
was blocked with phosphate-buffered saline (PBS) containing 5%
skimmed milk at room temperature for 1 h and then incubated
at 4 C overnight with an anti-his antibody (Pierce), at a dilution
of 1:3000 in the same solution. After washing 4 times with PBS
containing 0.05% Tween 20 (PBST) for 15 min each, the membrane
was incubated with a horseradish peroxidase (HRP)-conjugated
anti-mouse secondary antibody (Pierce) diluted 1:2500 in PBST.
Prior to development, the membrane was washed 4 times with
PBST for 15 min each. Finally, the proteins were detected using
the ECL system (Merck Millipore), and the membrane was visual-
ized using an ImageQuant LAS4000 mini system (GE Healthcare
Life Sciences).
Statistical analysis
All enzyme assays were conducted in four replicates, and an
unpaired t-test of independent experiments was performed using
GraphPad Prism software (GraphPad Software). The results were
considered signiﬁcant at a p-value 6 0.05.Results
Expression, puriﬁcation and refolding of recombinant CES1
The cDNA coding region of CES1 isoform a (amino acid residues
20–568; NCBI Reference Sequence: NP_001020366.1) was ampli-
ﬁed by PCR and cloned into the EcoRI and XhoI sites of the pET28a
expression vector (Fig. 1) for recombinant expression in E. coli BL21
(DE3). It is worth noting that CES1 isoform a is one amino acid
longer than the previously reported isoform b. Isoform a has a
longer signal peptide, of 19 amino acids, whereas isoform b has a
signal peptide of only 18. As a consequence, the numbering of
Fig. 2. SDS–PAGE analysis of recombinant WT CES1 expressed at different temperatures. (A) Cells were grown at 37 C, induced with 0.5 mM IPTG and incubated at 25 C for
4 h before harvest. Lane M, molecular mass marker proteins; lane 1, uninduced cells; lane 2, induced cells; lane 3, inclusion bodies and lane 4, soluble fraction. (B) Cells were
grown at 25 C and induced with 0.5 mM IPTG; lane 1, uninduced cells; lane 2, induced cells; lane 3, inclusion bodies and lane 4, soluble fraction. The arrow indicates the
expected size of recombinant CES1.
Fig. 3. SDS–PAGE analysis of recombinant WT CES1 expressed at 25 C in the presence of additives in the growth medium. (A) Final concentration of 1% glycerol at the time of
induction; Lane M, molecular mass marker proteins; lane 1, uninduced cells; lane 2, induced cells; lane 3, inclusion bodies and lane 4, soluble fraction. (B) A ﬁnal
concentration of 0.2 M sorbitol was added to growth medium at the time of induction; lane 1, uninduced cells; lane 2, induced cells; lane 3, inclusion bodies and lane 4,
soluble fraction. The arrow indicates the expected size of recombinant CES1.
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pared to the previous reports for isoform b. As shown in Fig. 2,
recombinant CES1 protein was expressed differently when grown
at different temperatures (37 C and 25 C before induction at
25 C). It was notable that the expression of CES1 grown at 25 C
was much higher than in cells grown at 37 C; however, the lower
temperature resulted in signiﬁcantly low solubility because of the
large quantity of protein expressed. As a result, the protein was
found in inclusion bodies; SDS–PAGE analysis revealed a band at
around 62 kDa corresponding to human CES1. While CES1 grown
at 37 C produced comparable amount of protein in both solubleand insoluble fractions. Unfortunately, we were unable to obtain
CES1 from the soluble fraction grown at 37 C due to low purity.
Therefore, attempts were made to improve the solubility of CES1,
with additives into growth medium. However, neither glycerol
nor sorbitol had an effect on CES1 solubility (Fig. 3), and the pro-
tein was puriﬁed under denaturing condition using 8 M urea to sol-
ubilize the misfolded protein. Puriﬁcation of the His-tagged
recombinant protein was accomplished in one step using afﬁnity
column chromatography. After puriﬁcation, urea and imidazole
were removed, as they interfere with the activity assay. The details
of the puriﬁcation of CES1s, both WT and mutants, are shown in
Table 2
Puriﬁcation of recombinant human CES1 from E. coli.
Construct Puriﬁcation step Total protein (mg) Speciﬁc activity
(lmol/min/mg)
Yield (%) Refolding yield (%)
WT Solubilized in 8 M urea 27.1 – 100 9.0
Cobalt resin column 13.4 – 49.4
Refolding 1.2 73 4.4
S76N Solubilized in 8 M urea 31.2 – 100 10.2
Cobalt resin column 16.6 – 53.2
Refolding 1.7 128 5.4
D204E Solubilized in 8 M urea 25.7 – 100 19.1
Cobalt resin column 11.6 – 45.1
Refolding 2.21 193 8.6
A270S Solubilized in 8 M urea 29.3 – 100 11.9
Cobalt resin column 12.6 – 43.0
Refolding 1.5 109 5.1
Fig. 4. SDS–PAGE analysis of puriﬁed recombinant CES1s, WT, S76N, D204E and
A270S, after refolding in 50 mM Tris–HCl, pH 7.5, containing 1% glycerol and 2 mM
b-mercaptoethanol.
Fig. 5. Intrinsic ﬂuorescence emission spectra of refolded CES1s, WT, S76N, D204E
and A270S. Protein refolding was performed in 50 mM Tris–HCl, pH 7.5, containing
1% glycerol and 2 mM b-mercaptoethanol.
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shown by SDS–PAGE (Fig. 4).
In this study, we used different combinations of various
additives and reducing agents for refolding recombinant CES1
(Table 1). CES1 has four cysteine residues and two disulﬁde bonds
(Fig. 1); therefore, the inﬂuence of reducing agents during the
refolding process was investigated. Refolding buffer Tris–HCl, pH
7.5, containing a combination of sorbitol, trehalose, sucrose and
b-mercaptoethanol failed to enhance solubility, resulting in non-
functional enzyme (Table 1). Interestingly, only the combination
of 1% glycerol and 2 mM b-mercaptoethanol was successful for
refolding CES1, resulting in a functionally active enzyme. When
b-mercaptoethanol was replaced with DTT, which is known to be
an effective reducing agent, no enzymatic activity was observed.
The proteins obtained after refolding were subjected to spectro-
scopic characterization, intrinsic ﬂuorescence and CD analyses.
The intrinsic ﬂuorescence and CD spectra are shown in Figs. 5
and 6, respectively. The recombinant WT and mutant proteins
exhibited similar patterns of intrinsic ﬂuorescence and CD spectra,
indicating that both WT and mutant CES1s share similar secondary
structure, with a-helices as the main ordered structure.Fig. 6. Circular dichroism (CD) spectra of refolded CES1s, WT, S76N, D204E and
A270S. Protein refolding was performed in 50 mM Tris–HCl, pH 7.5, containing 1%
glycerol and 2 mM b-mercaptoethanol.Enzymatic activity assay
Enzymatic assays were performed in Tris–HCl, pH 7.5. The
recombinant CES1 enzymes were catalytically active after
refolding in buffer containing 1% glycerol and 2 mM b-mercap-
toethanol (Fig. 7). The kinetic parameters (KM, kcat and Vmax) of
WT and non-synonymous variant CES1s were determined for thepNPA substrate by measuring the rate of enzymatic formation of
pNP at different substrate concentrations and ﬁtting the obtained
data to the Michaelis–Menten equation with a nonlinear
Fig. 7. A representative time course of pNPA hydrolysis by WT CES1. The reaction
was performed in a 1 ml volume containing Tris–HCl, pH 7.5, absolute ethanol,
100 mM pNPA and 20 ll puriﬁed WT CES1 at 37 C. Hydrolysis was determined
after incubating the reaction at 37 C for 10 min, and the formation of pNP was
followed at 405 nm for 10 min. A blank reaction was performed by replacing the
enzyme with buffer.
Fig. 8. A representative Michaelis–Menten plot of WT CES1. Enzyme kinetics of
pNPA hydrolysis catalyzed by WT CES1. The initial velocity was obtained by
subtracting the blank hydrolysis from the enzymatic hydrolysis at each substrate
concentration.
Table 3
Kinetic parameters of CES1, WT and mutants. Data are expressed as the mean ± stan-
dard deviation (S.D.).
Construct KM (lM) Vmax (lmol/min/mg) kcat (s1)
Wild type 579 ± 79 73 ± 4 7.6 ± 0.4
S76N 389 ± 81 128 ± 10 13 ± 1
D204E 417 ± 98 193 ± 15 20 ± 2
A270S 263 ± 53 109 ± 6 11 ± 0.6
Table 4
Comparison of speciﬁc activity of human CES1 toward pNPA.
Expression system Speciﬁc activity
(lmol/min/mg)
References
Insect (Sf9) 41 ± 2 Williams et al. [11]
Insect (Sf21) 18 ± 1 Nishi et al. [3]
Mammalian (COS7) 81 ± 4 Wadkins et al. [6]
Mammalian (Flp-In-293) 0.49 ± 0.01 Zhu et al. [9]
Bacteria (BL21 DE3) 73 ± 4 This study
Fig. 9. Western blot analysis of puriﬁed 6His recombinant CES1, WT, S76N, D204E
and A270S after refolding in 50 mM Tris–HCl, pH 7.5, containing 1% glycerol and
2 mM b-mercaptoethanol. Proteins were immunodetected using an anti-His (N-
term) antibody.
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observed for recombinant CES1 (Fig. 8), and the kinetic parameters
are shown in Table 3. WT CES1 demonstrated promising hydrolysis
of pNPA, with KM, kcat and Vmax values of 579 ± 79 lM, 7.6 ± 0.4 s1
and 73 ± 4 lmol/min/mg protein, respectively. When compared to
other expression systems, the puriﬁed WT CES1 from the present
study exhibited signiﬁcant speciﬁc activity toward pNPA (Table 4).
Each of the natural mutants exhibited different enzymatic activi-
ties when compared to the WT enzyme (p-value 6 0.05). The Vmax
values of S76N, D204E and A270S were 128 ± 10, 193 ± 15 and
109 ± 6 lmol/min/mg protein, respectively, higher than that ofWT. The KM values of the mutants were 389 ± 81, 417 ± 98 and
263 ± 53 lM for S76N, D204E and A270S, respectively. Though
the mutants showed smaller KM values than WT, they were still
in a comparable range. This result suggested that the binding afﬁn-
ity of the enzyme toward pNPA is not greatly altered by mutation
at residues 76 and 204, whereas the mutation at position 270
results in a binding afﬁnity that is 2-fold greater than that of
WT. The kcat values of S76N, D204E and A270S were 13 ± 1,
20 ± 2, 11 ± 0.6 s1, respectively, higher than that of the WT
enzyme.
Western blot analysis
A Western blot analysis was performed to conﬁrm the expres-
sion of recombinant CES1. Fig. 9 shows the Western blot analysis
of the WT and mutant proteins. All the recombinant proteins were
expressed at similar levels, except for D204E, which was expressed
at a lower level than the other constructs.
Discussion
CES1 plays an important role in metabolism of drugs, such as
cocaine and heroin, including oseltamivir, as well as the activation
of various xenobiotics [2,4,5,9]. In addition, this enzyme also
catalyzes the hydrolysis of long-chain fatty acids and thioesters.
Owing to its signiﬁcance, extensive work has been performed to
investigate the role of CES1 using recombinant protein and charac-
terization employing a variety of substrates, including heroin,
cocaine, oseltamivir, aspirin, clopidogrel, methyl-4-nitrobenzoate
and pNPA [2,4,8,11]. However, such studies have been carried
out mainly in eukaryotic cells, mostly insect and mammalian cells
[2,5,9,11]. Although eukaryotic expression systems are commonly
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usually produce small to moderate amounts of protein. In contrast,
bacterial expression systems are inexpensive, easy to handle and
produce large amounts of protein and are therefore widely used
in the production of numerous proteins. Morton and Potter [14]
attempted to express human CES1 in bacteria and to increase the
solubility of the protein by using different bacterial strains
(Top10 and BL21 (DE3)), reducing the growth temperature and
renaturing the protein with guanidine and other detergents but
failed to obtain the functional enzyme, as the protein was largely
expressed as inclusion bodies.
Molecular chaperones such as GroES/GroEL are known to facil-
itate the folding of many proteins expressed in bacteria and have
been applied and proven to be successful in the expression of
human aromatase and aldehyde dehydrogenase [24,25]. Initially,
we co-expressed GroES/GroEL and pET32a–CES1 in Origami
(DE3) cells grown at 37 C and induced with IPTG when the absor-
bance at 600 nm reached 0.6, harvesting the cultures after 16 h of
induction. Unfortunately, the protein was primarily expressed in
the insoluble fraction, and puriﬁcation of soluble CES1 was not
attainable because of inadequate purity (data not shown). Because
using pET32a as an expression vector and co-expressing with
GroES/GroEL failed to yield a practical amount of soluble protein,
we continued our expression experiments in the absence of these
molecular chaperones and sub-cloned CES1 into the pET28a vector.
Subsequently, we attempted to increase the solubility of the pro-
tein by lowering the temperature before and after IPTG induction.
As shown in Fig. 2A, a small band at approximately 62 kDa was
observed when the cells were grown at 37 C and induced at
25 C, indicating the improved solubility of WT CES1. The small sol-
uble CES1 protein was then subjected to puriﬁcation using an
immobilized-metal afﬁnity column; however, this puriﬁcation
was unsuccessful, as a large amount of contaminating proteins
was present (data not shown). Expressing and inducing CES1 at
25 C had no inﬂuence on solubility (Fig. 2B). Although decreasing
the growth temperature to 25 C resulted in a higher yield of pro-
tein, this was accompanied by low solubility, as a large amount of
protein was expressed in inclusion bodies (Fig. 2B). Thereafter, we
performed expression at 25 C because of the greater protein yield.
Chemical chaperones are known to help correct the conforma-
tion of proteins via different mechanisms. Improved solubility
has been observed for the cytokinin biosynthetic enzyme dimeth-
ylallyl pyrophosphate: 50-AMP transferase (DMAPP: AMP transfer-
ase), green ﬂuorescent protein (GFP) and single-chain Fv when
sorbitol was added to the growth medium [26–28]. Moreover,
the addition of 0.4% glycerol to the culture medium enhanced
the solubility of a human phenylalanine hydroxylase mutant
enzyme [36], resulting in both higher solubility and activity.
Accordingly, at the time of induction, we included chemical
chaperones, glycerol and sorbitol in the growth medium at ﬁnal
concentrations of 1% and 0.2 M, respectively but found that these
additives were not beneﬁcial for expressing CES1 (Fig. 3).
Recombinant CES1 was signiﬁcantly expressed in the insoluble
fraction, and we puriﬁed under denaturing conditions in which
8 M urea was used to solubilize the insoluble protein. Additives
such as trehalose, sorbitol, glycerol, arginine and sucrose may
enhance the solubility of numerous proteins when included in the
refolding buffer [17,19,29,31–33]. In addition, it has been shown
that the presence of reducing agents also improves protein solubil-
ity [19,29]. Therefore, themisfolded protein obtainedwas subjected
to refolding in the presence of a combination of different chemical
chaperones, trehalose, sucrose, glycerol and sorbitol, and reducing
agents, b-mercaptoethanol and dithiothreitol (DTT) (Table 1). For-
tunately, refolding in Tris–HCl, pH 7.5 containing 1% glycerol and
2 mM b-mercaptoethanol was successful, producing functional
CES1. After refolding, intrinsic ﬂuorescence and CD spectra for therecombinant WT and mutant proteins were analyzed. Each CES1
protein showed the same pattern of intrinsic ﬂuorescence and CD
spectra. The spectroscopic characterization results indicate that
both WT and mutant CES1s share similar secondary structure, with
a-helices as the main ordered structure. The presence of mutations
at residues 76, 204 and 270 had no effect on the secondary structure
of human CES1 (Figs. 5 and 6). According to the procedures pre-
sented here, it was evident that the refolding method was efﬁcient
for bothWT andmutant CES1: all of the recombinantswere catalyt-
ically active, with high speciﬁc activity (Table 3). The yield in the
ﬁrst puriﬁcation step ranged from 43% to 53%, and the refolding
yield ranged between 9% and 19%, resulting in 1–2 mg protein,
which is practical for functional characterization.
To verify that our recombinant CES1 was functionally active
after refolding, we investigated the catalytic activity of the WT
enzyme. pNPA was chosen as the substrate to study CES1 activity
because this compound is a sensitive and established model sub-
strate. As shown in Fig. 7, WT CES1 was hydrolytically active
toward pNPA. In comparison with recombinant human CES1
expressed in eukaryotic systems, our refolded CES1 exhibited a
signiﬁcant speciﬁc activity comparable to that of CES1 expressed
in mammalian COS7 cells. In fact, our refolded CES1 showed
greater speciﬁc activity than the enzyme expressed in insect and
mammalian (Flp-In-293) cells (Table 4). This ﬁnding indicates that
recombinant CES1 expressed in E. coli and refolded in Tris–HCl, pH
7.5, containing 1% glycerol and 2 mM b-mercaptoethanol is cata-
lytically active, showing similar activity to the native enzyme. As
the WT enzyme was successfully puriﬁed and refolded, producing
a catalytically active enzyme, we then sought to examine whether
this refolding system is applicable to the mutant proteins. Addi-
tionally, the effect of these mutations on the catalytic activity of
CES1 would provide information regarding the signiﬁcance of poly-
morphisms to metabolism. Therefore, we created three natural
mutants, which are reported in the literature and a database of sin-
gle-nucleotide polymorphism (SNP) from NCBI (NCBI: dbSNP),
S76N, D204E and A270 [10,37]. These three variants were included
in our study because the frequency of these mutations is relatively
high, as reported by NCBI: dbSNP [37]. Our results illustrated that
the recombinant mutant proteins were catalytically active, with
kinetic properties similar to that of the WT enzyme (Table 3). This
result indicates that these mutations, S76N, D204E and A270S, are
not critical for the catalytic activity of the enzyme, as they had
little effect on activity. Apparently, these mutant enzymes are
moderately more active than the WT enzyme. This is in agreement
with an in vitro functional study on the enzymatic activity of
nonsynonymous variants (G18V, S82L and A269S; numbering
according to CES1 isoform b) that reported no signiﬁcant difference
from that of the WT enzyme with regard to the hydrolysis of
clopidogrel, 2-oxo-clopidogrel and methylphenidate [10]. Other
natural mutations (V21I, I32V, S58N, C70F, G156D, R182H,
D186E; numbering according to CES1 isoform b) also exhibited
activity comparable to the WT enzyme regarding the hydrolysis
of oseltamivir and clopidogrel, with the exception that C70F was
catalytically inactive against both substrates, whereas R182H
showed markedly reduced activity toward oseltamivir [4,5].
Conclusions
In present study, we, for the ﬁrst time, developed an efﬁcient
method for the refolding of denaturant-solubilized recombinant
human CES1 while retaining the biological activity of the enzyme.
We found that the combination of 1% glycerol and 2 mM b-mercap-
toethanol in Tris–HCl at pH 7.5 signiﬁcantly improved the solubil-
ity of denaturant-solubilized human CES1 during the refolding
process. This refolding condition was applicable to the WT enzyme
as well as three natural variants. The biological function of CES1
U. Boonyuen et al. / Protein Expression and Puriﬁcation 107 (2015) 68–75 75was retained after refolding, and this puriﬁed His-tagged CES1 can
be used directly without removing the fusion tag. To the best of our
knowledge, no details of CES1 refolding have been reported before.
The methods presented in this study allow the production of a
signiﬁcant amount as well as a functionally active human CES1
in a bacterial expression system for further functional studies on
the biological role of this enzyme.
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